

APPLICANT(S): RUBINSTEIN, Abraham  
SERIAL NO.: 10/630,917  
FILED: July 31, 2003  
Page 2

### AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1. (Amended) A synchronous drug delivery composition comprising:

[a] an erodable, hydrogel-forming polymeric matrix which comprises

a) ~~a hydrogel polymer, wherein said hydrogel polymer is blended with blend~~  
which comprises a hydrophilic polymeric cellulose derivative and a  
hydrophobic polymeric methacrylic acid derivative polymer, so as to form an  
erodible matrix;

b) a drug;

c) an agent which enhances intestinal drug absorption; and

d) an agent which inhibits intestinal drug degradation[;],

wherein erosion of said erodable matrix, permits synchronous release of said drug, said agent  
which enhances intestinal drug absorption and said agent which inhibits intestinal drug  
degradation and said hydrogel polymer.

2-4 (Cancelled)

5. (previously presented) A pharmaceutical composition comprising the synchronous drug delivery composition of claim 1 and a carrier or diluent.

6. (currently amended) A pharmaceutical composition comprising the synchronous drug delivery composition of claim [2] 28 and a carrier or diluent.

7. (currently amended) A pharmaceutical composition comprising the synchronous drug delivery composition of claim [3] 29 and a carrier or diluent.

8. (cancelled) A pharmaceutical composition comprising the synchronous drug delivery composition of claim 4 and a carrier or diluent.

9. (previously presented) A drug delivery composition according to claim 1, wherein the composition is in the form of a plain matrix tablet.

APPLICANT(S): RUBINSTEIN, Abraham  
SERIAL NO.: 10/630,917  
FILED: July 31, 2003  
Page 3

10. (currently amended) A drug delivery composition according to claim [2] 28, wherein the composition is in the form of a plain matrix tablet.

11. (currently amended) A drug delivery composition according to claim [3] 29, wherein the composition is in the form of a plain matrix tablet.

12-16 (cancelled)

17 (previously presented) A drug delivery composition according to claim 1, wherein the composition is coated with an enterocoating.

18. (currently amended) A drug delivery composition according to claim 28, wherein the composition is coated with an enterocoating.

19. (currently amended) A drug delivery composition according to claim[3] 29, wherein the composition is coated with an enterocoating.

20-22 (cancelled)

23. (currently amended) A method of synchronically ~~release~~ releasing a drug, an agent which inhibits intestinal drug degradation and an agent which enhances intestinal drug absorption, comprising the step of administering the composition of claim [4]1.

24. (previously presented) A method of increasing the bioavailability of a drug, comprising the step of administering the drug delivery composition according to claim 1.

25. (currently amended) A method of increasing the bioavailability of a drug, comprising the step of administering the drug delivery composition according to claim 28.

26. (currently amended) A method of increasing the bioavailability of a drug, comprising the step of administering the drug delivery composition according to claim [3]29.

27. (cancelled) A method of increasing the bioavailability of a drug comprising the step of administering the drug delivery composition according to claim 4.

28. (New) A drug delivery composition according to claim 1, wherein said cellulose derivative is hydroxypropylmethyl cellulose, methylcellulose, carboxymethyl cellulose or hydroxypropyl cellulose.

APPLICANT(S): RUBINSTEIN, Abraham  
SERIAL NO.: 10/630,917  
FILED: July 31, 2003  
Page 4

29. (New) A drug delivery composition according to claim 1, wherein said methacrylic acid derivative is Eudragit® RL.